Advancing Science: The Case Against Animal Testing

For more than a century, animal experiments have been touted as a cornerstone of biomedical and toxicological research. From drug safety assessments to disease modeling, animals have been used under the assumption that they provide predictive insights into human biology. Yet mounting evidence demonstrates that animal testing is often unreliable, scientifically outdated, and increasingly unnecessary in the face of rapidly advancing non-animal methods (NAMs).

It is time to reconsider the role of animal testing in research. This article explores the reasons against animal testing, the alternatives available, and the ethical implications of continuing this practice.

A scientist using advanced technology to explore alternatives to animal testing.

The Historical Context of Animal Testing

Animal testing has a long history, dating back to ancient Greece. Scientists used animals to study anatomy and physiology. Over the years, this practice evolved, and by the 20th century, it became a standard method for testing drugs and cosmetics.

However, as science has progressed, so has our understanding of the limitations of animal testing. Many drugs that are safe for animals have proven harmful to humans. This raises questions about the reliability of animal testing as a predictor of human responses.

Scientific Limitations of Animal Testing

Numerous studies have highlighted the low predictive value of animal models for human diseases and drug development:

• Translational failure in drug development: A review in the British Medical Journal found that fewer than 10% of promising results from animal studies translate into effective human therapies (Hackam & Redelmeier, 2006). - That is over 90% of drugs that worked on animals do not work in humans.

• Species differences: Fundamental biological and genetic differences mean that results in rodents or non-human primates often fail to predict human outcomes (van der Worp et al., 2010).

• Toxicology unreliability: Leist & Hartung (2013) argue that traditional toxicity testing in animals is not only slow and costly but also poorly predictive for human safety, leading to false positives and negatives.

• Some of the translational failures have resulted in human substantial health damage during the clinical trials. - Key Examples are the Thalidomide — severe fetal malformations (1950s–60s), TGN1412 (anti-CD28 monoclonal antibody) — life-threatening cytokine storm in first-in-human trial (2006), Fialuridine (FIAU) — fatal liver failure and lactic acidosis in hepatitis B trial (early 1990s), Troglitazone (Rezulin) — idiosyncratic, sometimes fatal hepatotoxicity (withdrawn) and Fenfluramine / Fen-Phen (appetite suppressants) — cardiac valvulopathy and pulmonary hypertension. (See more details and references on this topic here)

These failures highlight that continuing to rely on animal models slows progress, misguides investment, and sometimes puts patients at risk.

The Rise of Non-Animal Methods (NAMs)

Innovations in biotechnology now allow researchers to model human biology with unprecedented accuracy:

• Organoids and organ-on-chips: Human-derived 3D organoids and microfluidic chips replicate organ-level functions, providing powerful platforms for disease modeling, toxicology, and drug testing (Marx et al., 2020).

• Computational modeling and AI: Predictive algorithms and physiologically based pharmacokinetic (PBPK) models simulate drug metabolism and toxicity with high fidelity to human physiology (Zhang et al., 2021).

• High-throughput in vitro assays: Human cell–based methods allow for rapid, scalable screening, already replacing animal tests in areas like skin and eye irritation (OECD, 2017).

These tools not only deliver results that are more human-relevant, but also reduce costs and accelerate timelines.

Policy and Regulatory Shifts

A global regulatory shift toward acceptance of NAMs is well underway:

• United States: The FDA Modernization Act 2.0 (2022) explicitly allows drug developers to use non-animal test methods in place of traditional animal studies for preclinical testing. FDA statements and roadmaps on NAMs (FDA announcement April 10, 2025). U.S. Food and Drug Administration; U.S. EPA announcement of mammal testing phase-out by 2035 (Sept 2019 and later policy updates); The National Institutes of Health (NIH) is investing heavily in organoid and chip-based platforms (NIH, 2023).

• European Union: The EU banned animal testing for cosmetics in 2013 and funds alternatives under the European Partnership for Alternative Approaches to Animal Testing (EPAA). In 2021, the European Parliament called for a comprehensive plan to phase out animal testing.

• OECD Guidelines: Several NAM-based assays (e.g., reconstructed human epidermis tests for skin irritation and corrosion) are validated and included in OECD regulatory guidelines, demonstrating international acceptance (OECD TG 439, TG 431).

These developments mark a paradigm shift where NAMs are no longer supplementary but credible replacements for animal experiments. (see comprehensive global shifts and roadmaps here)

Ethical and Scientific Imperative

The ethical case against animal testing is well established: animals used in laboratories experience stress, pain, and confinement. However, the scientific case is now equally urgent. Continuing to channel resources into outdated animal models diverts attention and funding from innovative, human-relevant approaches that can accelerate breakthroughs in medicine, environmental health, and toxicology.

Conclusion

The momentum is clear: animal testing is not the future of science. With NAMs offering more reliable, cost-effective, and ethically responsible solutions, and with regulators increasingly embracing them, the path forward is evident. Redirecting investment, policy, and scientific culture toward these methods is not only an ethical necessity but also the surest way to advance human health and protect the environment.

References

• Hackam, D. G., & Redelmeier, D. A. (2006). Translation of research evidence from animals to humans. BMJ, 334(7586), 197.

• van der Worp, H. B., et al. (2010). Can animal models of disease reliably inform human studies? PLoS Medicine, 7(3), e1000245.

• Leist, M., & Hartung, T. (2013). Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. ALTEX, 30(2), 227–240.

• Marx, U., et al. (2020). Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. Nature Reviews Materials, 5, 841–856.

• Zhang, M., et al. (2021). Computational approaches for drug safety evaluation and biomarker discovery. Frontiers in Pharmacology, 12, 657235.

• OECD (2017). Test No. 439: In vitro Skin Irritation: Reconstructed Human Epidermis Test Method. OECD Guidelines for the Testing of Chemicals.

• U.S. Congress (2022). FDA Modernization Act 2.0.

• National Institutes of Health (NIH). (2023). Non-Animal Methods and Technologies. Retrieved from nih.gov.

• European Parliament (2021). Resolution on plans and actions to accelerate a transition to innovation without the use of animals in research, regulatory testing and education.

Let us work together to create a world where research is conducted responsibly and compassionately. The time for change is now, and every voice matters in this important conversation.

Join Us